title: 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response.
authors.affiliation: Department of Nuclear Medicine, University Hospital of Muenster, Muenster, Germany. rahbar@uni-muenster.de.
authors.forename: Kambiz
authors.identifier: http://orcid.org/0000-0002-4591-4055
authors.initials: K
authors.lastname: Rahbar
authors.affiliation: Department of Urology, University Hospital of Muenster, Muenster, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Bögemann
authors.affiliation: Department of Nuclear Medicine, University Hospital of Bonn, Bonn, Germany.
authors.forename: Hojjat
authors.initials: H
authors.lastname: Ahmadzadehfar
mesh_terms: D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D004151:Dipeptides / Q000627:therapeutic use*; D006573:Heterocyclic Compounds, 1-Ring / Q000627:therapeutic use*; D006801:Humans; D008187:Lutetium; D008297:Male; D017063:Outcome Assessment, Health Care / Q000379:methods*; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: C000610110:Pluvicto; D004151:Dipeptides; D006573:Heterocyclic Compounds, 1-Ring; D019275:Radiopharmaceuticals; D008187:Lutetium; D017430:Prostate-Specific Antigen
keywords: PSMA-617; Radioligand therapy; mCRPC